Theranostics 2018, Vol. 8, Issue 18 4995 Ivyspring International Publisher Theranostics 2018; 8(18): 4995-5011. doi: 10.7150/thno.26627 Research Paper Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling Zhi Huang,1# Wei Zhou,1# Yongtao Li,1 Mei Cao, 1 Tianqi Wang, 1 Yakun Ma, 1 Qingxiang Guo, 1 Xin Wang,1 Chao Zhang,1 Chenglan Zhang,1 Wenzhi Shen,6 Yanhua Liu,2 Yanan Chen,2 Jianyu Zheng,5 Shengyong 4 1,2,3 1,2,3 Yang, Yan Fan and Rong Xiang 1. Department of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin 300071, China 2. State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China 3. 2011 Project Collaborative Innovation Center for Biotherapy of Ministry of Education, Tianjin 300071, China 4. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy and Sichuan University, Chengdu 610041, China 5. State Key Laboratory and Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China 6. Department of Pathology and Institute of Precision Medicine, Jining Medical University, Jining 272067, China. # Zhi Huang and Wei Zhou contributed equally to this work. Corresponding authors: Yan Fan: E-mail:
[email protected]; Rong Xiang: E-mail:
[email protected]. © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.